Controversy news from FiercePharma
News
Hassan gets $30M pay package
Fred Hassan (photo) may have his hands full these days, defending Vytorin and Zetia while cutting jobs and costs. But... Read more...
FDA wants to lengthen stent testing
Looking for hard evidence that the FDA is tightening approval standards? Here it is. The agency today proposed tougher clinical trial guidelines for drug-coated stents. Rather than letting new... Read more...
Congress: Were Enhance results secret?
Finally, someone asked the question we've been wanting to ask ourselves: Even if the Enhance study data remained blinded, could Merck or Schering-Plough have divined its overall sway? Sen. Charles... Read more...
Stent sales stabilize as rival enters
In the stent world today, it's good news, good news, and bad news. First, the bad news: Last year's fourth quarter was the worst in several years for drug-coated stents. In December, only 62 percent... Read more...
J&J CEO talks tech
What do you obsess about when you're CEO of Johnson & Johnson? Well, it's not Band-Aids. In an interview with the Financial Times, Bill Weldon (Read more...
Amgen in new talks over ESA safety
Amgen is sitting down with regulators for a little frank talk about the safety warnings on Aranesp... Read more...
Docs reconsider drug-coated stents
Well, maybe drug-coated stents aren't so bad after all. Some doctors are now saying that the medical community Read more...
Study: Coated stents aren't cost-effective
If drug-eluting stents were on the shelves at Costco, most value-conscious customers wouldn't buy. A new Swiss study has found that the coated stents aren't cost-effective for most patients--and... Read more...
Teva inks deal to sell generic Avandia
Remember when, as a kid, you really, really wanted something for your birthday--but then it didn't seem so great once you got it? We wonder if that's the way Teva Pharmaceuticals feels now it's... Read more...
Shire recalls some Daytrana shipments
Mom, I can't get my ADHD patch on! Shire is recalling some lots of Daytrana, its attention... Read more...
Get more Controversy coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
